Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
Authors
Keywords
-
Journal
ADVANCES IN THERAPY
Volume 29, Issue 3, Pages 202-217
Publisher
Springer Nature
Online
2012-02-10
DOI
10.1007/s12325-011-0099-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Early Evaluation of Tumoral Response to Antiangiogenic Therapy by Arterial Spin Labeling Perfusion Magnetic Resonance Imaging and Susceptibility Weighted Imaging in a Patient With Recurrent Glioblastoma Receiving Bevacizumab
- (2011) Slim Fellah et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib
- (2010) A. A. M. van der Veldt et al. CLINICAL CANCER RESEARCH
- Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma
- (2010) Ana M. Molina et al. INVESTIGATIONAL NEW DRUGS
- Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206
- (2010) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
- (2009) Brett E. Houk et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients
- (2009) B. E. Houk et al. CLINICAL CANCER RESEARCH
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
- (2009) Martin E Gore et al. LANCET ONCOLOGY
- Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis
- (2008) Xiaolei Zhu et al. ACTA ONCOLOGICA
- The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation
- (2008) P Wolter et al. BRITISH JOURNAL OF CANCER
- Tyrosine kinase inhibitors and modifications of thyroid function tests: a review
- (2008) Frédéric Illouz et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
- (2008) Manuela Schmidinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib
- (2008) S. E. Rosenbaum et al. SUPPORTIVE CARE IN CANCER
- Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma
- (2007) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started